Anti-CD30 chimeric antigen receptor T cell therapy (Yake Biotechnology)

N/A

Report date: 2024/05/15 16:09:08

Base Information

Drug NameAnti-CD30 chimeric antigen receptor T cell therapy (Yake Biotechnology)
Drug Alias NameCD30 CART cell therapy (Yake Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 8
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaN/A
Originator CompaniesShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A